A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines. - MT10109L in the Treatment of Glabellar Lines

Allergan Ltd.0 个研究点目标入组 225 人开始时间: 2019年6月3日最近更新: 2021年4月5日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 225

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- Participant must be = 18 years of age and considered to be an adult in her/his local jurisdiction at the time of signing the informed consent.
•- Moderate to severe GL at maximum frown (as assessed by both the investigator and participant; investigator and participant ratings must be the same) using the FWS.
•- Participants must have sufficient visual acuity without the use of eyeglasses (contact lens use acceptable) to accurately assess their GL lines, in the opinion of the investigator.
•- Male and female
•- Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period.
•- Female participants of childbearing potential must have a negative urine pregnancy test before each study intervention. A female is considered NOT to be of childbearing potential if she is premenarchal, postmenopausal (at least 12 consecutive months without menstruation), or permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral oophorectomy).
•- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
•- Written informed consent from the participant has been obtained prior to any study-related procedures.
•- Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable. (eg, Written Authorization for Use and Release of Health and Research Study Information [US sites] and written Data Protection consent [EU sites]).
•- Ability to follow study instructions, including completing study assessment tools without any assistance or alteration to the assessment tools and likely to complete all required visits.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 216
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 9

排除标准

•- Any condition which precludes a participant’s ability to comply with study requirements, including completion of the study visits or inability to read, understand, and/or self-assess GL severity using FWS.
•- Known immunization or hypersensitivity to any botulinum toxin serotype.
•- Any medical condition that may put the participant at increased risk with exposure to MT10109L including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function.
•- Any history of significant cardiovascular disease, family history of long QT syndrome, or a clinically significant electrocardiogram (ECG) abnormality at the Screening Visit.
•- Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, or the inability to substantially lessen facial lines even by physically spreading them apart, as determined by the investigator.
•- Any brow or eyelid ptosis, as determined by the investigator.
•- Infection or skin disorder at the injection sites.
•- History of facial nerve palsy.
•- Any uncontrolled systemic disease.
•- Recent history of alcohol or drug abuse based on the investigator’s judgment
•- Anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than study intervention).
•- Anticipated need for surgery or overnight hospitalization during the study.
•- Prior exposure to botulinum toxin of any serotype for any reason
•- Any of the following procedures or treatments occurring in the specified period before enrollment (Day 1):
•- 3 months: any facial nonablative resurfacing laser, light or ultrasound treatment, microdermabrasion, or superficial peels
•- 6 months: any facial cosmetic procedure with medium depth or deep depth chemical peels (eg, trichloroacetic acid [TCA] and phenol); periorbital, mid-facial, or upper-facial skin resurfacing; or permanent make-up in the mid-facial (extending from inferior orbital margin to level of the nasal base) or upper facial areas
•- 12 months: any periorbital, mid-facial, or upper-facial treatment with nonpermanent soft tissue fillers
•- Participants on topical retinoid therapy and/or topical hormone cream applied to the face, who have not been on a consistent dose regimen for at least 6 months before enrollment and who are unable to maintain the same regimen for the study.
•- Participants on oral retinoid therapy within 1 year before study enrollment.
•- Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow lift, or related procedures (eg, eyelid [blepharoplasty] and/or eyebrow surgery).
•- Prior facial treatment with permanent soft tissue fillers, synthetic implantation (eg, Gore-Tex®), and/or autologous fat transplantation.
•- Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.
•- Females who are pregnant, nursing, or planning a pregnancy during the study.
•- Participants who plan for an extended absence away from the immediate area of the study site that would preclude them from returning for all protocol specified study visits.
•- Participants who, in the investigator’s opinion, are unable or unwilling to maintain their standardized skin care regimen throughout the study period.
•- The participant has a condition or is in a situation which, in the investigator’s opini

研究者

发起方

Allergan Ltd.

相似试验

进行中（未招募）

1 期

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-ResponseStudy to Evaluate the Safety and Efficacy of a Single Treatment of BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex Injected into the Prostatefor the Treatment of Lower Urinary Tract Symptoms in Patients due to BenignProstatic HyperplasiaPatients with lower urinary tract symptoms due to Benign Prostatic HyperplasiaMedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasia

EUCTR2005-004281-17-CZAllergan Inc.350

进行中（未招募）

不适用

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a Treatment with BOTOX® as Applicable in Patients with Idiopathic Overactive Bladder with Urinary IncontinencePatients with symptoms of idiopathic overactive bladder (frequency and urgency) and urinary incontinence, whose symptoms have not been adequately managed with anticholinergic therapyMedDRA version: 12.0Level: LLTClassification code 10059617Term: Overactive bladder

EUCTR2009-013088-20-NLAllergan Ltd534

未知

3 期

A Multicenter, Double-Blind, Randomized, Placebo-Controlled PhaseIII Study to Evaluate the Efficacy and Safety of OVF in Opioid tolerant Patients With Cancer and Breakthrough Pain.

JPRN-jRCT2080221194Taiho Pharmaceutical Co., Ltd.

进行中（未招募）

不适用

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate theSafety and Antiretroviral Activity of MK-0518 in Combination With an OptimizedBackground Therapy (OBT), Versus Optimized Background Therapy Alone, in HIVInfected Patients With Documented Resistance to at Least 1 Drug in Each of the 3Classes of Licensed Oral Antiretroviral Therapies - Safety, PK, and Efficacy of MK-0518 plus OBT vs OBT Alone in HIV+nspecified human immuno-deficiency virus [HIV] diseaseMedDRA version: 7.0Level: LLTClassification code 10020162

EUCTR2005-005127-34-PTMerck Sharp & Dohme, Lda.366

进行中（未招募）

不适用

EUCTR2005-004281-17-ATAllergan Inc.350